TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38064262
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily steps
Study: 38064262
Drug: Step trajectories
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step trajectories during treatment
Study: 38064454
Drug: Extracorporeal cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal cardiac shock wave therapy (ECSW) combined with optimal drug therapy
Study: 38065203
Drug: Sabatolimab plus
Normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabatolimab plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Study: 38065203
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Study: 38065203
Drug: Sabatolimab plus
Normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabatolimab plus hypomethylating agent
Study: 38065203
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus hypomethylating agent
Study: 38065326
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy after 6 months in patients with PDL at the lobe
Study: 38065906
Drug: CKD-495 75
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-495 75 mg
Study: 38065906
Drug: AAF 60
Normalized name: Filgrastim-aafi
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAF 60 mg
Study: 38066442
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10 cc sterile processed acellular hAF once daily for up to 5 days
Study: 38066471
Drug: Rectal microbicide
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal microbicide modalities (douche, insert, suppository)
Study: 38066522
Drug: anti-PD-1 immunotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 immunotherapy
Study: 38066597
Drug: Exenatide (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (once weekly) plus standard treatment
Study: 38368603
Drug: Somapacitan (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.16 mg/kg/week)
Study: 38368603
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (0.034 mg/kg/day)
Study: 38067150
Drug: IL-6 protein
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 protein levels of ≥6.4 pg/mL
Study: 38068830
Drug: Automated Self-Administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Self-Administered 24-h Dietary Assessment Tool (ASA24) for food records.
Study: 38070031
Drug: IFNβ-1a plus
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFNβ-1a plus 2 gm of metformin once daily
Study: 38070635
Drug: PCSK9 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCSK9 inhibitors (alirocumab 150 mg sc or evolocumab 140 mg sc every two weeks)
Study: 38070683
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract (CE) 500 mg flavanols/d, including 80 mg (-)-epicatechin
Study: 38070682
Drug: Folic acid-containing
Normalized name: Folic acid-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid-containing supplements during treatment
Study: 38070682
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid in plasma during treatment
Study: 38070892
Drug: Antibody levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody levels
Study: 38071986
Drug: Reduction group
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction group (ICS-formoterol dose tapering)
Study: 38071990
Drug: SIM01 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIM01 (10 billion colony-forming units in sachets twice daily)
Study: 38072158
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg intravenously every 3 weeks for ≤93 weeks
Study: 38072183
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (2800 IU/d)
Study: 38072183
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose vitamin D3 (400 IU/d)
Study: 38072494
Drug: Low birth
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low birth weight (<2500 g)
Study: 38072513
Drug: Lasofoxifene 5
Normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Lasofoxifene 5 mg/day plus abemaciclib 150 mg b.i.d until disease progression/toxicity
Study: 38072514
Drug: Lasofoxifene 5
Normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Lasofoxifene 5 mg daily
Study: 38072514
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (days 1, 15, and 29, then every 4 weeks)
Study: 38072625
Drug: Lisocabtagene maraleucel
Normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10
Study: 38072743
Drug: Pomalidomide, Bortezomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide, Bortezomib, and Dexamethasone (PVd) with bortezomib dose adjustment
Study: 38073038
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg daily for 14 days
Study: 38073563
Drug: Hypertensive individuals
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive individuals (systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or use of antihypertensive medications) at 1 year postpartum
Study: 38074312
Drug: Sotrovimab treatment
Normalized name: sotrovimab
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Sotrovimab treatment
Study: 38074489
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for obesity management, combined with sessions with a dietitian and a kinesiologist, for 16 weeks.
Study: 38074489
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving sessions with a dietitian and a kinesiologist, without cognitive behavioral therapy, for 16 weeks.
Study: 38074489
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for obesity management.
Study: 38074719
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC mixed with tobacco
Study: 38074719
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg THC mixed with tobacco
Study: 38075956
Drug: Home-based Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based Exercise Therapy (HBET) program with behavior change intervention and smartphone app
Study: 38076348
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (eGFR <30 ml/min/1.73 m²)
Study: 38076348
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (eGFR ≥30 and <60 ml/min/1.73 m²)
Study: 38076348
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (eGFR ≥60 ml/min/1.73 m²)
Study: 38076682
Drug: ADHD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD group (medicated daily for ADHD)
Study: 38077624
Drug: MF59 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvanted trivalent influenza vaccine (aTIV)
Study: 38078711
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of tributaries
Study: 38078711
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of perforating veins
Study: 38078870
Drug: Tirzepatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (10 or 15 mg, once-weekly subcutaneous)
Study: 38078898
Drug: Camonsertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camonsertib monotherapy
Study: 38079084
Drug: PG-HPG nanoemulsion
Normalized name: linoleamidopropyl PG-dimonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-HPG nanoemulsion lubricant eye drops, self-administered one drop four times daily for 28 ± 2 days
Study: 38079089
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once daily orally until disease progression or unacceptable toxicity
Study: 38079095
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg oral daily
Study: 38079095
Drug: Probe drug
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probe drug alone
Study: 38081585
Drug: Walnut diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut diet (15% energy, 30-60 g/d; 2.6-5.2 g C18:3n-3/d)
Study: 38082227
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg dexmedetomidine
Study: 38082231
Drug: FPSS (flavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPSS (flavored PEG and sulfate solution)
Study: 38082248
Drug: Weekly reminders
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reminders (WR) group - received phone reminders 1x/week for 10 weeks
Study: 38082351
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (MCI) program including education of ICU professionals, identification of patients at risk for agitation, formulation of a multidisciplinary person-centered care plan, and protocolized goal-directed light sedation using dexmedetomidine.
Study: 38084725
Drug: 90 g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g of donor faeces once into the large intestine
Study: 38084725
Drug: 90 g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g of donor faeces once into the small intestine
Study: 38084725
Drug: 90 g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g of donor faeces twice into the small intestine
Study: 38084760
Drug: Daratumumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab combined with VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group)
Study: 38084760
Drug: VRd induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group)
Study: 38084906
Drug: Daily samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily samples for 10 days
Study: 38084906
Drug: Daily rapid
Normalized name: Clotam Rapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rapid antigen tests (RATs)
Study: 38085312
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg orally twice per day from enrollment through delivery
Study: 38085312
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice per day from enrollment through delivery
Study: 38085470
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) administration of CoronaVac
Study: 38085470
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of CoronaVac
Study: 38085846
Drug: Riliprubart 30
Normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riliprubart 30 mg/kg
Study: 38085846
Drug: Riliprubart 15
Normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riliprubart 15 mg/kg
Study: 38085846
Drug: Riliprubart (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riliprubart (both doses)
Study: 38086444
Drug: Buprenorphine (offered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (offered to participants taking prescription opioid medications at an average dose of ≥20 morphine milligram equivalents per day)
Study: 38086587
Drug: Medical hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical hypnosis (MH) and cardiac coherence (CC) training, starting 7 days before surgery.
Study: 38086587
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment to manage preoperative anxiety (Control).
Study: 38086587
Drug: Medical hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical hypnosis (MH) and cardiac coherence (CC) training.
Study: 38086595
Drug: Methylphenidate (long-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (long-release capsule, doses 18-36-54 mg)
Study: 38086595
Drug: Lisdexamphetamine (LDX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamphetamine (LDX, 30-50-70 mg)
Study: 38086998
Drug: Imaradenant 50
Normalized name: Imaradenant
DrugBank: Imaradenant (DB16192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaradenant 50 mg QD
Study: 38086998
Drug: Imaradenant 75
Normalized name: Imaradenant
DrugBank: Imaradenant (DB16192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaradenant 75 mg QD
Study: 38086998
Drug: Imaradenant (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaradenant (50 mg and 75 mg QD)
Study: 38088154
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity measured by wearable smartwatch (Huawei smartwatch)
Study: 38088154
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step counts
Study: 38088156
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression treatment with eltrombopag (Group B)
Study: 38088156
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression treatment (Group A)
Study: 38089057
Drug: Peroral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral administration of a capsule containing purified DMT and harmine
Study: 38089057
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of an oromucosal harmine tablet and an intranasal DMT spray
Study: 38089061
Drug: Combined supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplement of standardized dry extracts of amla
Study: 38089924
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g broccoli sprouts
Study: 38090266
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1a (sc IFN β-1a) treatment
Study: 38090987
Drug: Eplerenone, 50
Normalized name: Eplerenone, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone, 50 mg, twice a day
Study: 38091531
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant influenza vaccine (Flublok Quadrivalent)
Study: 38091531
Drug: Standard-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose influenza vaccines
Study: 38091530
Drug: mRNA-1345 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 (50 μg)
Study: 38092009
Drug: Golidocitinib 150
Normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met.
Study: 38092009
Drug: Golidocitinib 150
Normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golidocitinib 150 mg once daily
Study: 38092151
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) supplementation at 800 μg/day for 12 weeks
Study: 38092153
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg oral daily)
Study: 38092225
Drug: Dupilumab 100/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 100/200 mg by bodyweight every 2 weeks for 52 weeks
Study: 38092272
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice nitrate-rich (BRJ-NO3), 800 mg of NO
Study: 38092790
Drug: Mazdutide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazdutide (up to 6 mg)
Study: 38092871
Drug: Elevated choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated choline levels (per SD, 11.49 μg/mL)
Study: 38092897
Drug: AP30663, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP30663, an inhibitor of the K channel
Study: 38093181
Drug: Low eosinophil
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low eosinophil count <0.01 G/L
Study: 38093181
Drug: Eosinophil count
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil count 0-0.07 G/L
Study: 38093181
Drug: Eosinophil count
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil count 0.07-0.172 G/L
Study: 38093181
Drug: Eosinophil count
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil count <0.01 G/L
Study: 38093439
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hgb threshold 7.0 g/dL)
Study: 38093439
Drug: Conservative transfusion
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative transfusion strategy (Hgb threshold 5.5 g/dL)
Study: 38093803
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioural therapy (iCBT) program for 9 weeks
Study: 38094620
Drug: FFT-MCC (Family-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFT-MCC (Family-focused therapy with MyCoachConnect app)
Study: 38094620
Drug: FFT-Track (Family-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFT-Track (Family-focused therapy with mood tracking only)
Study: 38094629
Drug: Tumor Treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Treating Fields (TTFields) therapy
Study: 38095657
Drug: Survodutide (dose-response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide (dose-response effects)
Study: 38095692
Drug: Ustekinumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (90 mg every 8 or 12 weeks)
Study: 38095878
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and atezolizumab (1200 mg every 3 weeks)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with bevacizumab
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy without bevacizumab
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with carboplatin
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with cisplatin
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with prior CRT
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy without prior CRT
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy in squamous type
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy in nonsquamous type
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with bevacizumab (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy without bevacizumab (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with carboplatin (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with cisplatin (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy with prior CRT (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy without prior CRT (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy in squamous type (intention-to-treat)
Study: 38095881
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy in nonsquamous type (intention-to-treat)
Study: 38095903
Drug: Weighted combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted combination of clinical predictors
Study: 38095899
Drug: Evidence-based checklist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based checklist administered every 6 hours from enrollment to organ retrieval.
Study: 38096002
Drug: Weekly medication
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly medication diary and standardized self-reports (both groups)